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RAF links RAS, one of the most potent human oncogenes, to its effector ERK and to proliferation.
This role is evolutionarily conserved, but while simpler multicellular organisms express one RAF,
mammals have three. This Minireview highlights common and divergent features of RAF paralogs,
their signaling outputs, and roles in tumorigenesis.The RAF family of enzymes comprises three evolutionarily
conserved cytosolic serine/threonine kinases (ARAF, BRAF
and RAF1, AKA CRAF). RAFs are best known for activating
ERK signaling, which transduces extracellular stimuli (e.g.,
growth factors) into a phosphorylation cascade to induce bio-
logical outcomes, including proliferation, migration, differentia-
tion, and survival. Activated downstream of the small G protein
RAS by a much-studied yet incompletely understood mecha-
nism, RAFs phosphorylate the dual-specificity kinase MEK,
which in turn activates ERK. ERK phosphorylates an impressive
roster of membrane, cytosolic, and nuclear targets; in contrast,
RAFs and MEK mainly phosphorylate one substrate, MEK for
RAF and ERK for MEK. Considering this stringent substrate
specificity and the fact that simpler organisms possess only
one Raf gene, the presence of three RAF isoforms in verte-
brates is intriguing. All paralogs contain three conserved re-
gions: the N-terminal CR1, comprising the Ras-binding domain
(RBD) and cysteine-rich domain (CRD), which stabilize the
inactive conformation; CR2, which contains residues important
for RAF membrane recruitment during activation; and CR3,
containing the kinase domain (Figure 1A). Phylogenetic com-
parisons reveal that BRAF is the isoform most similar to the
single RAF kinase homolog LIN-45 in Caenorhabditis elegans
and D-Raf/lethal-1-polehole in Drosophila, suggesting that
BRAF is the prototypical RAF kinase, while ARAF and RAF1
may have evolved to carry out additional functions. Upon stim-
ulation by growth factors, active RAS recruits RAFs to the
plasma membrane and promotes the formation of functionally
asymmetric RAF homo- and heterodimers in which one mono-
mer, typically BRAF, allosterically stimulates the kinase activity
of the other. Phosphorylation/dephosphorylation of several
serine residues is also necessary for activation. In particular,
the residue required for binding of 14-3-3 to the CR2 (Ser259
in RAF1) must be dephosphorylated for membrane recruitment
and activation; in contrast, the C-terminal 14-3-3 binding site
(Ser 621 in RAF1) must be phosphorylated to facilitate Raf
dimerization. Finally, the N region upstream of CR3 must be
negatively charged for activation. In ARAF and RAF1, this is
achieved by phosphorylation of specific residues, while in
BRAF, this region features a negatively charged Asp residueand a constitutively phosphorylated Ser residue. Thus, BRAF
is poised for activation by RAS.
The efficiency with which the three RAFs phosphorylate MEK
also varies, with BRAF andARAF being themost and least potent
MEK activators, respectively. This may reflect not only BRAF’s
higher kinase activity, but also its ability to heterodimerize with
MEK in the cytosol of quiescent cells. It is envisioned that,
upon pathway activation, this preformed complex translocates
to the membrane, forming an active tetramer with another
RAF:MEK dimer. Intriguingly, the BRAF:MEK complex is dissoci-
ated by BRAF mutations promoting BRAF:RAF1 dimerization,
suggesting that MEK may negatively regulate RAF dimerization
and pathway activation by competing with RAF1 for binding
(Figure 1B) (Haling et al., 2014).
Ultimately, the ERK pathway is switched off by dephosphory-
lation of its components. Even before this happens, however,
activated ERK regulates its upstream components via negative
feedback phosphorylation, dimming RAS activation by the
guanine nucleotide exchange factor SOS (Son of Sevenless),
reducing RAF dimerization and activity by phosphorylating
both BRAF and RAF1, and decreasing the activity of MEK1/
MEK2 dimers by phosphorylating MEK1. Thus, activated ERK
exerts tight temporal control on the RAS signal transduction.
Pathway activation was recently reviewed in Cseh et al. (2014).
The module described above is the minimal version of the
RAF/MEK/ERK pathway. However, the extent of its activation,
the strength of the signal it transduces, and its biological outputs
are also determined by the interaction of pathway components
with scaffold proteins that insulate and localize the response,
the best known of which is the RAF-related pseudokinase
KSR (kinase suppressor of ras). Mutations in these scaffolds
are rare in cancer (http://www.cbioportal.org/), and protein-
protein interactions are notoriously difficult therapeutic targets.
Recently, however, Jameson et al. (2013) have shown that dis-
rupting the function of the RAF/MEK/ERK scaffold IQGAP1 (IQ
motif-containing Ras GTPase-activating-like protein) inhibits
RAS and RAF-driven tumorigenesis, circumventing the acquired
resistance to RAF andMEK inhibitors. Thus, appreciating the full
complexity of the pathway will be instrumental in defining new
potential intervention points.Cell 161, May 21, 2015 ª2015 Elsevier Inc. 967
Figure 1. RAF Paralogs’ Structure, Activa-
tion, and Function
(A) Comparison of human ARAF, BRAF, and
RAF1 and the worm homolog lin-45. The three
conserved regions CR1, CR2, and CR3, the
structural domains they contain (RAS-binding
domain [RBD]; cysteine-rich domain [CRD]; and
kinase domain), and phosphorylated residues
(positive, yellow outline; negative, red outline)
regulating RAF activation are marked.
(B) Model of RAS-driven RAF activation. (B)RAF
and MEK form a cytosolic complex in quiescent
cells. Upon activation, they translocate to the
membrane, where a putative heterotetramer (two
RAF, two MEK molecules) drives ERK activation.
(C) Functions of RAF paralogs in development and
tumorigenesis. Solid red lines denote inhibition;
broken red lines denote negative feedback. Line
thickness is proportional to the strength and
significance of the interactions. NSCLC, non-small
cell lung cancer.Unexpected but Essential—Catalytic and Non-catalytic
Roles of RAF
Conditional knockout models have provided insight into the
essential functions and complexity of Raf paralogs (Figure 1C;
reviewed in Cseh et al., 2014). Braf ablation causes embryonic
lethality through defective placenta development and, when
restricted to neuronal precursors, in a progressive neurodegen-
erative disease caused by a failure in oligodendrocyte differenti-
ation and myelination. These phenotypes correlate with reduced
MEK/ERK activation in the relevant cells and organs and can be
phenocopied by treating wild-type cells with MEK inhibitors.
Thus, BRAF is the main ERK activator in vivo, whether through
its own MEK kinase activity or through RAF1 activation. In
contrast, none of the phenotypes observed in RAF1-deficient
cells or tissues is accompanied or caused by a decrease in
ERK signaling. If anything, ERK phosphorylation is higher in
Raf1 knockout cells and tissues. RAF1 is an essential regulator
of keratinocyte migration and of the stability of nascent cell-cell
junctions in endothelial cells. In embryonic liver and fibroblasts, it
regulates apoptosis via the internalization of the death receptor
FAS. All of these essential functions of RAF1 can be attributed
to its ability to bind the Rho-activated, cytoskeleton-based
kinase ROKa (Rho-associated kinase a), bringing it to specific
subcellular localizations and/or dimming its activity. In addition,968 Cell 161, May 21, 2015 ª2015 Elsevier Inc.RAF1 promotes cell survival by antago-
nizing the proapoptotic kinase ASK1.
ASK1 hyperactivation correlates with
the defects in postnatal development
observed in RAF1-deficient cardiac mus-
cle, and Ask1 ablation rescues this
(Yamaguchi et al., 2004). Finally, RAF1
competes with another RAS effector,
RASSF1 (Ras association domain-con-
taining protein 1) for the binding to
MST2 (mammalian STE20-like kinase 2),
preventing MST2 activation and impact-
ing the Hippo pathway. Interaction with
MST2 was also shown for ARAF and
BRAF. Interestingly, the strength of inter-action and inhibition inversely correlates with RAF kinase activ-
ity; it is strongest in the case of ARAF, while BRAF interaction
withMST2 is extremely weak and possibly depends on RAF1 (re-
viewed in Nguyen et al., 2015). The roles of ARAF and RAF1 in
MST2 regulation, while intriguing, have not been demonstrated
conclusively in vivo. It would thus appear that BRAF is the only
RAF kinase lacking a role in protein-protein interaction-based
cross-talk with other pathways; it is possible, however, that
through its binding to RAF1 or ARAF, BRAF may compete with
other interactors, ultimately impacting the cross-talk described
above. In support of this hypothesis, in keratinocytes, Braf abla-
tion results in increased complex formation between RAF1 and
ROKa (Doma et al., 2013).
RAF in Cancer–—More Than Just ERK
RAF was discovered in 1983 as an oncogene causing fibro-
sarcoma in mice. Nearly 30 years later, hundreds of reports
elucidated roles of RAF paralogs in cancer, either as drivers or
as critical downstream effectors of activated RAS (reviewed in
Maurer et al., 2011; Holderfield et al., 2014), providing an excel-
lent rationale to design inhibitors of this pathway.
These reports can be broadly divided in three categories,
depending on the approaches taken: (1) large-scale sequencing
studies, such as the one that first identified BRAF mutations in
melanoma, which establish the identity and frequency of
mutations in a specific tumor type or across a panel of cancer
cell lines; (2) studies assessing the ability of RAF mutants,
expressed in specific cells or tissues, to drive tumorigenesis;
(3) studies assessing the requirement for a specific isoform in
specific cancers.
Somatic RAF mutations in human cancers are unequally
distributed among isoforms. While mutations activating
BRAF are frequent in hairy cell leukemia (100%), melanoma
(50%–60%), and thyroid cancer (40%–60%), RAF1 and ARAF
mutations are very rare and are associated with some lung
adenocarcinomas and, in the case of ARAF, intrahepatic cholan-
giocarcinoma (Sia et al., 2015). The higher frequency of BRAF
mutations compared to ARAF and RAF1 mutations correlates
well with BRAF’s higher basal activity toward MEK and its
simpler mechanism of activation. While one single mutation is
sufficient to activate BRAF, other RAF isoforms may require
multiple mutations or additional upstream events to reach
maximal activation. The most frequently observed mutation, a
valine 600 / glutamic acid substitution (BRAFV600E), disrupts
the inactive conformation of the kinase and abolishes the
requirement for dimerization, inducing persistent activation of
BRAFV600E monomers and, consequently, of the MEK/ERK
pathway. BRAFV600E is oncogenic in cultured cells and in many
tissues, as demonstrated by Cre-inducible expression of the
mutant Braf allele. Depending on the tissue, BRAFV600E pro-
motes cancer development (in thyrocytes or in the gastrointes-
tinal tract) or causes benign tumors, which become malignant
upon loss of tumor suppressors (lung and melanocytes). Tumor
formation is always accompanied by ERK activation and is
sensitive to MEK inhibitors.
Less common BRAF mutants with impaired kinase activity
have also been identified. These mutants can constitutively acti-
vateMEK/ERK pathway, in particular in the context of oncogenic
RAS, thanks to their intrinsic ability to bind and allosterically
activate RAF1. Accordingly, in the only in vivo study of this
sort, melanocyte-restricted expression of the kinase-impaired,
dimerization-competent BRAFD594A mutant is tumorigenic only
when combined with an activating KRAS mutation (Heidorn
et al., 2010).
Unlike BRAF, ARAF and RAF1 mutations are rare in human
cancers. A S214A-activating ARAF mutation has been identified
in lung adenocarcinoma patients, and S214A ARAF has been
shown to transform immortalized airway cells (Imielinski et al.,
2014). Two further ARAFmutations, G322S in the kinase domain
and N217I in the CR2, have been identified in intrahepatic chol-
angiocarcinoma. Both constitutively activate MEK/ERK but fail
to transform NIH 3T3 cells (Sia et al., 2015). Thus, their onco-
genic potential is unclear. Beyond activating mutations, ARAF
has been proposed to act as a scaffold protein by binding to
BRAF and stabilizing BRAF:RAF1 heterodimers, particularly in
the presence of RAF inhibitors (Rebocho and Marais, 2013).
The overall frequency of RAF1 mutations in cancer is below
1% (http://www.cbioportal.org). The most frequent, S257 and
S259 mutations, were reported in several tumor types, including
lung adenocarcinoma and colorectal cancer (Imielinski et al.,
2014). Intriguingly, S259 mutations prevent phosphorylation of
the residue that restrains RAF1 membrane recruitment by RAS,making RAF1 more susceptible to activation. While mutations
are rare, overexpression of RAF1 occurs in bladder cancer,
hepatocellular carcinoma, squamous cell carcinoma, and lung
adenocarcinoma (Maurer et al., 2011).
Based on the results of these studies, the roles of BRAF and
RAF1 in cancer are just as distinct as in development, with
BRAF driving MEK/ERK activation and RAF1 performing other
essential functions. This hypothesis has been tested in RAS-
driven models of epithelial cancers combined with conditional
ablation of either BRaf or Raf1.
Both paralogs are essential for development andmaintenance
of RAS-induced epidermal tumors. BRAF promotes ERK activa-
tion and cell proliferation, and its ablation halts tumor growth
(Kern et al., 2013). In contrast, the role of RAF1 is ERK indepen-
dent and relies on its ability to bind and inhibit ROKa, preventing
keratinocytes dedifferentiation. Raf1 ablation rapidly induces
keratinocyte differentiation, causing complete tumor regression
in this system (Ehrenreiter et al., 2009). The discrepancy between
the two Raf isoforms is even more evident in a KRAS-driven
model of NSCLC, in which BRAF is completely dispensable while
RAF1 plays an essential role that, despite being unknown, was
shown to be MEK independent (Blasco et al., 2011; Karreth
et al., 2011). Thus, RAF1 has essential but MEK-independent
roles in these two models. RAF1, however, is dispensable for
the development of KRAS-driven pancreatic cancer in which
the PI3K/PDK1 axis is essential. The role of BRAF has not
been tested in this system, but it has been previously shown
that BRAFV600E can drive tumorigenesis in the pancreas (Eser
et al., 2014).
Together, these results are consistent with the idea that BRAF
is the entry point in the MEK/ERK pathway and promotes
proliferation either downstream of RAS or, when mutated, as
an oncogenic driver. In contrast, RAF1 mutations are rare, but
at least in skin and lung epithelia, the impact of their ERK inde-
pendent functions on RAS-driven tumorigenesis is profound.
Targeting RAF for Therapeutic Purposes
The deregulation of the RAF/MEK/ERK signaling observed
in human cancer has boosted the hunt for drugs specific to
this pathway. RAF inhibitors have been developed and tested;
some have gained FDA approval for treatment of specific
cancers, possibly in the context of personalized medicine. Ad-
vantages and drawbacks of RAF inhibitors have been recently
reviewed (Lito et al., 2013; Holderfield et al., 2014; Cseh et al.,
2014).
Vemurafenib and dabrafenib, which specifically target
BRAFV600E monomers, have brought unprecedented clinical
benefits to patients with BRAFV600E-expressing melanoma.
They are also used in hairy cell leukemias refractory to conven-
tional treatment with purine analogs and are currently being
tested in BRAFV600E-positive NSCLC patients. Unfortunately,
these inhibitors are ineffective in other BRAFV600E-expressing
malignancies such as metastatic colorectal carcinoma and
thyroid cancer. In the latter, a negative feedback loop attenu-
ating growth factor receptor (e.g., EGFR) signaling is lost upon
inhibitor treatment; as a result, the attainable level of ERK inhibi-
tion never reaches the 80% required for therapeutic effects.
This feedback reactivation is not observed in melanomas, whichCell 161, May 21, 2015 ª2015 Elsevier Inc. 969
express low levels of EGFR, unless they upregulate this receptor.
Thus, the presence of the BRAFV600E mutation does not always
guarantee responsiveness to BRAF inhibitors, and the cellular
context in which they are used must be considered as a key
factor. In addition, most tumors develop resistance to BRAF
inhibitors within months. Multiple mechanisms of acquired resis-
tance exist. Cells escapeRAF inhibition by increasing expression
of receptor tyrosine kinases, which can reactivate ERK or signal
through parallel survival pathways such as PI3K-AKT, diminish-
ing the dependence on ERK pathway. ERK reactivation mecha-
nisms by pathway components include BRAFV600E amplification
or the expression of inhibitor-insensitive splice variants, as well
as RAF1 amplification or mutational activation of NRAS, which
preferentially signals through RAF1. Alternatively, BRAF can be
bypassed by activating MEK mutations or by overexpressing
COT (cancer Osaka thyroid oncogene) kinase, which activates
MEK in a RAF-independent manner.
Another undesirable consequence of RAF inhibition is para-
doxical ERK activation. This is observed in BRAF wild-type cells
in the presence of activated RAS and is due to the fact that the
inhibitors, unless present in saturating concentrations, promote
RAF dimerization and therefore activation. This mechanism is
responsible for the occurrence of skin tumors in patients treated
with vemurafenib (20%–26%) and dabrafenib (6%–11%). To
prevent MEK/ERK activation, a combination of dabrafenib and
the MEK inhibitor trametinib has been approved for the treat-
ment of BRAFV600E/K melanoma. Unfortunately, melanomas
can circumvent RAF/MEK inhibition by combining mechanisms
of resistance to BRAF inhibitors. Intriguingly, double-resistant
cells are drug addicted, which may be exploited for therapy
schedules involving intermittent cycles of inhibitor (Moriceau
et al., 2015).
New efforts are required to develop improved strategies that
combine the excellent clinical response of RAF inhibition with
reduced side effects and prolonged efficacy. A newgeneration of
inhibitors termed ‘‘paradox breakers’’ have been designed and
tested in preclinical settings. Two compounds (CCT196969
and CCT241161), which inhibit RAF1 and BRAFV600E (but not
wild-type BRAF), as well as SRC-family kinases, which are
downstream of receptor tyrosine kinases and contribute to
ERK reactivation in resistant cells, showed improved efficacy
in BRAF and NRAS mutant melanoma. The same drugs also
inhibit the growth of patient-derived, BRAF mutant melanoma
xenografts resistant to the vemurafenib analog PLX4720,
implying that they may be beneficial as second-line treatment
(Girotti et al., 2015).
Conclusions and Perspectives
It is clear that the RAF paralogs have very distinct essential func-
tions in spite of their synergy in ERK signaling. BRAF, the main
ERK activator, is the target of somatic mutations that increase
its enzymatic activity and can drive tumorigenesis in a number
of systems. RAF1, in contrast, is not essential for ERK activation.
Its function in development and tumorigenesis is mainly the
protein-protein interaction-based cross-talk with other signaling
pathways, which generates non-oncogene addiction in RAS-
driven models. Consistently, RAF1 is not the target of activating
mutations, but it is often found overexpressed in tumors.970 Cell 161, May 21, 2015 ª2015 Elsevier Inc.Currently, most efforts in inhibitor development are directed in
finding more potent, less toxic inhibitors of RAF kinase activity or
inhibitor combinations to prevent the insurgence of resistance.
As we learn about RAF paralogs and their role in tumors, inhibi-
tors targeting both their kinase-dependent and kinase-indepen-
dent functions may become a more efficient, safer therapeutic
alternative.
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